Madrigal Pharmaceuticals, Inc. with ticker code (MDGL) have now 12 analysts in total covering the stock. The consensus rating is pointing to ‘buy’. The target price High/Low ranges between 416 and 224 suggesting an average Analsyt target price of $331.17. Now with the previous closing price of $285.49 this indicates there is a potential upside of 16.0%. The day 50 moving average is $269.97 while the 200 day moving average is $179.46. The total market capitalization for the company now stands at 5.16B. The current stock price for Targa Resources Corp. is currently 282.16 USD
The potential market cap would be $5,986,186,612 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of -, revenue per share of – and a -70.78% return on assets.
Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH). The Company’s product candidate, resmetirom, is a proprietary, liver-directed, selective thyroid hormone receptor-B (THR-B), agonist being developed as a once-daily oral pill for the treatment of NASH. NASH is a more advanced form of non-alcoholic fatty liver disease (NAFLD). NASH is a liver disease that affects people with metabolic diseases, such as obesity and diabetes and non-alcoholic fatty liver disease (NAFLD).
